Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $172,636.60 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 6,995 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.68, for a total value of $172,636.60. Following the completion of the sale, the chief financial officer directly owned 86,896 shares of the company’s stock, valued at approximately $2,144,593.28. This represents a 7.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vaseem Mahboob also recently made the following trade(s):

• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Up 4.5%

NASDAQ:KMTS opened at $26.40 on Friday. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a twelve month low of $14.30 and a twelve month high of $30.00. The company has a market cap of $1.55 billion, a PE ratio of -10.91 and a beta of 0.58. The company’s 50 day moving average is $22.96 and its two-hundred day moving average is $22.57.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The company had revenue of $28.64 million during the quarter. Analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Kestra Medical Technologies

Several large investors have recently made changes to their positions in KMTS. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies during the fourth quarter valued at $31,000. Russell Investments Group Ltd. raised its position in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after acquiring an additional 474 shares during the period. BNP Paribas Financial Markets raised its position in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of Kestra Medical Technologies during the 4th quarter worth about $72,000. Finally, Brown Brothers Harriman & Co. grew its position in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares during the period.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. BTIG Research lifted their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.